Reproxalap

DB16688InvestigationalSmall molecule

Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. NS-2... NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.

Mechanism: Reproxalap inhibits Reactive Aldehyde Species (RASP) and is being investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome.
Curator reviewed · 1 reference
Formula / weight: C₁₂H₁₃ClN₂O · 236.7 g/mol (avg)
Code names: ADX-102 · ALD-102 · NS-2

Resolves to

Compound

UNIIF0GIZ22IJHCAS916056-79-6ChEMBLCHEMBL4297210

Structure

InChIKeyGUHFUVLKYSQIOQ-UHFFFAOYSA-NSMILESCC(C)(O)C1=NC2=C(C=C1N)C=C(Cl)C=C2

What you can answer from here — as of April 23, 2025

11Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Reproxalap, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account